Abstract:Inappropriately activation of renin-angiotensin-aldosterone system induced renal fibrosis is characterized by partial epithelial-to-mesenchymal transition. Previously, we have indicated that miR-29b-3p in inhibiting partial epithelial-to-mesenchymal transition by negatively regulating extracellular matrix gene expression in the kidney. Despite the critical role of miR-29b-3p in fibrosis, the molecular mechanisms by which miR-29b-3p is regulated under the condition of profibrotic stimuli are largely unknown. Our aim is to search for the long noncoding RNA that mediated sponge regulatory on miR-29b-3p, and whether the long noncoding RNA could be activated by renin-angiotensin-aldosterone system and its consequent effects on renal fibrosis. Bioinformatics analysis predicted that Tug1 might directly bound to miR-29b-3p and function as a competing endogenous RNA. Dual-luciferase reporter assay, fluorescence in situ hybridization, and real-time polymerase chain reaction were performed to indicate that Tug1 interact with miR-29b-3p in a sequence-specific manner. Decreased Tug1 led to an increase in extracellular matrix measured by Western blot, and this effect was enhanced by miR-29b-3p measured by real-time polymerase chain reaction and Western blot, suggesting cross-regulation between the RNAs. Bioinformatics analysis predicted that mineralocorticoid receptor might bind to long noncoding RNA Tug1. Notably, mineralocorticoid receptor antagonism reduced Tug1 expression in the presence or absence of angiotensin II or aldosterone measured by real-time polymerase chain reaction, and RNA immunoprecipitation assays confirmed that the mineralocorticoid receptor directly bound to Tug1. Finally, we confirmed that Tug1 expression was enhanced in fibrotic compared with nonfibrotic human renal biopsy samples using RNA-in situ hybridization. Our findings provide novel insights into the molecular mechanism of Ang II-induced renal fibrosis and identify the Tug1-miR-29b-3p axis as an important target of MR activation.

The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

MiR-29a modulates the angiogenic properties of human endothelial cells.

miR-29 family: A potential therapeutic target for cardiovascular disease

Abstract 059: Mir-29 is Required for Normal Endothelium-dependent Vasodilation and Protects Against Hypertension

MicroRNA-29a Promotes Smooth Muscle Cell Differentiation from Stem Cells by Targeting YY1

MicroRNA-29b Inhibits Diabetic Nephropathy in Db/db Mice.

Long Noncoding RNA <i>Tug1</i> Promotes Angiotensin II-Induced Renal Fibrosis by Binding to Mineralocorticoid Receptor and Negatively Regulating MicroR-29b-3p

Mir‐29 Contributes to Normal Endothelial Function and Can Restore It in Cardiometabolic Disorders

TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29.

Abstract 15822: Mir-29 Contributes to Normal Endothelial Function in Healthy Human Resistance Arterioles and Restores Endothelium-Dependent Vasodilation in Type 2 Diabetes

MicroRNA-26a: An Emerging Regulator of Renal Biology and Disease.

Aberrant expression of miR-29b-3p influences heart development and cardiomyocyte proliferation by targeting NOTCH2

miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation

MicroRNA-29c Is a Signature MicroRNA under High Glucose Conditions That Targets Sprouty Homolog 1, and Its in Vivo Knockdown Prevents Progression of Diabetic Nephropathy*

Mir-29 Contributes To Normal Endothelial Function In Healthy Human Resistance Arterioles And Restores Endothelium-Dependent Vasodilation In Type 2 Diabetes

Downregulation of microRNA-29b in cancer and fibrosis: molecular insights and clinical implications

Mir-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice

MicroRNA-29a-3p Attenuates ET-1-induced Hypertrophic Responses in H9c2 Cardiomyocytes

MicroRNA: a new frontier in kidney and blood pressure research.

Overexpression of MiR-29b-3p Inhibits Atrial Remodeling in Rats by Targeting PDGF-B Signaling Pathway

Diverse roles of miR-29 in cancer (review).